Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
A variant in the GLP1R gene is associated with differences in weight loss, while a variant in the GIPR gene predicts nausea specifically in people taking tirzepatide (Mounjaro), not semaglutide (Wegovy or Ozempic)
Physicians also screen for exclusion criteria including pregnancy plans, certain gastrointestinal conditions, and drug interactions that could affect safety or efficacy
Purchase Your Evaluation Includes a metabolic, thyroid, and insulin panel personalized to your intake, a 60 minute evaluation with one of our providers, your GLP-1 candidacy assessment, and your personalized treatment plan
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
See our what are peptides explainer for broader context on the wider research-compound landscape
Key risks include pancreatitis, gallbladder disease, potential thyroid C-cell tumours, and altered levothyroxine requirements due to weight changes
